Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Hoelzer D, Walewski J, Doehner H, Viardot A, Hiddemann W, Spiekermann K, Serve H, Duehrsen U, Huettmann A, Thiel E, Dengler J, Kneba M, Schaich M, Schmidt-Wolf IGH, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Goekbuget N (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: American Society of Hematology
Book Volume: 124
Pages Range: 3870-9
Journal Issue: 26
DOI: 10.1182/blood-2014-03-563627
Abstract
This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antibody rituximab. From 2002 to 2011, 363 patients 16 to 85 years old were recruited in 98 centers. Treatment consisted of 6 5-day chemotherapy cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy. Patients >55 years old received a reduced regimen. Rituximab was given before each cycle and twice as maintenance, for a total of 8 doses. The rate of complete remission was 88% (319/363); overall survival (OS) at 5 years, 80%; and progression-free survival, 71%; with significant difference between adolescents, adults, and elderly patients (OS rate of 90%, 84%, and 62%, respectively). Full treatment could be applied in 86% of the patients. The most important prognostic factors were International Prognostic Index (IPI) score (0-2 vs 3-5; P = .0005), age-adjusted IPI score (0-1 vs 2-3; P = .0001), and gender (male vs female; P = .004). The high cure rate in this prospective trial with a substantial number of participating hospitals demonstrates the efficacy and feasibility of chemoimmunotherapy, even in elderly patients. This trial was registered at www.clinicaltrials.gov as #NCT00199082.
Authors with CRIS profile
Involved external institutions
Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie
Poland (PL)
Klinikum der Universität München (Großhadern und Innenstadt)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Rheinische Friedrich-Wilhelms-Universität Bonn
Germany (DE)
Klinikverbund Bremen (Gesundheit Nord)
Germany (DE)
Poland (PL)
Klinikum der Universität München (Großhadern und Innenstadt)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Rheinische Friedrich-Wilhelms-Universität Bonn
Germany (DE)
Klinikverbund Bremen (Gesundheit Nord)
Germany (DE)
How to cite
APA:
Hoelzer, D., Walewski, J., Doehner, H., Viardot, A., Hiddemann, W., Spiekermann, K.,... Goekbuget, N. (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-9. https://doi.org/10.1182/blood-2014-03-563627
MLA:
Hoelzer, Dieter, et al. "Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial." Blood 124.26 (2014): 3870-9.
BibTeX: Download